Being overweight or obese is associated with harboring a gut microbial community not capable of metabolizing the soy isoflavone daidzein to O- desmethylangolensin in peri- and post-menopausal women

Miller, Lindsey M.; Lampe, Johanna W.; Newton, Katherine M.; Gundersen, Gabrielle; Fuller, Sharon; Reed, Susan D.; Frankenfeld, Cara L.

doi:10.1016/j.maturitas.2017.02.006

Cited by 38 publications

(35 citation statements)

References 42 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Remarkably, the distribution of urolithin metabotypes in the population has been reported to be mainly determined by aging . Regarding isoflavones, two metabotypes have been identified based on the excretion of the microbial metabolite equol, i.e., equol‐producers and non‐producers, although a third potential metabotype is currently being considered regarding those individuals that are not able to produce the metabolite O ‐desmethylangolensin (ODMA) . Therefore, i) polyphenol gut metabotypes are based on a binary response (presence vs absence of metabolites), ii) their possible confirmation requires the analysis of large cohorts, and iii) the inclusion of a number of potential variables such as age is mandatory in the multivariate analyses.…”

Section: Discussionmentioning

confidence: 99%

The Human Metabolism of Nuts Proanthocyanidins does not Reveal Urinary Metabolites Consistent with Distinctive Gut Microbiota Metabotypes

Cortés‐Martín

Selma

Espı́n

et al. 2018

Molecular Nutrition Food Res

View full text Add to dashboard Cite

Scope The stratification of individuals according to their gut microbiota metabotypes is crucial to understand the polyphenols health effects as reported for isoflavones and ellagitannins. To date, the existence of human gut microbiota metabotypes associated with proanthocyanidins (PAs) catabolism remains unclear. Methods & Results Sixty‐eight healthy volunteers (40 adolescents and 28 adults) consumed a mixture of walnuts, almonds, and hazelnuts for 3 days, providing 163.65 ± 11.74 mg of PAs. Urine samples were analyzed by ultra‐performance LC–ESI‐quadrupole time‐of‐flight. Twenty‐one isomers of conjugated valerolactones and valeric acids were identified, which derived from six valerolactone and valeric acid precursors after analysis of hydrolyzed urine. This combined approach allowed discrimination between the inter‐individual variability related to phase‐II enzymes polymorphisms and the metabolism of PAs by the gut microbiota. No associations of PAs metabolism with gender, age, BMI, or ellagitannin metabotypes were found. Different quantitative excretion was observed after multivariate analysis but not true gut microbiota metabotypes associated with PAs catabolism. Conclusions The metabolism of PAs does not reveal urinary metabolites consistent with distinctive gut microbiota metabotypes. The quantitative excretion of metabolites is inadequate to stratify individuals due to the strong influence of external factors (source, quantity, and time of the last intake of PAs, etc.).

show abstract

Section: Discussionmentioning

confidence: 99%

The Human Metabolism of Nuts Proanthocyanidins does not Reveal Urinary Metabolites Consistent with Distinctive Gut Microbiota Metabotypes

Cortés‐Martín

Selma

Espı́n

et al. 2018

Molecular Nutrition Food Res

View full text Add to dashboard Cite

show abstract

“…[ 166 ] described that the ODMA‐producer, but not the equol‐producer metabotype, was associated with obesity in adults, the same group reported that obese individuals were more likely to be ODMA non‐producers. [ 172 ] It seems that there are many variables potentially involved in the distribution of daidzein‐related metabotypes so that more controlled studies in larger cohorts from different geographical origins are required.…”

Section: Human Polyphenol‐related Metabotypes As Biomarkers Of the Gumentioning

confidence: 99%

“…Miller et al. [ 172 ] also suggested the association of the ODMA non‐producer metabotype with obesity in those peri‐ and pos enopausal women that harbored a specific gut microbial ecology not capable of metabolizing daidzein to ODMA, although no specific dietary intervention was performed. Overall, these observations cannot conclude whether the presence of the microbial community associated with equol and(or) ODMA production is somehow involved in the effects exerted by the corresponding postbiotics equol and ODMA.…”

Section: Human Polyphenol‐related Metabotypes As Biomarkers Of the Gumentioning

confidence: 99%

Where to Look into the Puzzle of Polyphenols and Health? The Postbiotics and Gut Microbiota Associated with Human Metabotypes

Cortés‐Martín

Selma

Tomás‐Barberán

et al. 2020

Molecular Nutrition Food Res

199

240

View full text Add to dashboard Cite

The full consensus on the role of dietary polyphenols as human-healthpromoting compounds remains elusive. The two-way interaction between polyphenols and gut microbiota (GM) (i.e., modulation of GM by polyphenols and their catabolism by the GM) is determinant in polyphenols' effects. The identification of human metabotypes associated with a differential gut microbial metabolism of polyphenols has opened new research scenarios to explain the inter-individual variability upon polyphenols consumption. The metabotypes unequivocally identified so far are those involved in the metabolism of isoflavones (equol and(or) O-desmethylangolesin producers versus non-producers) and ellagic acid (urolithin metabotypes, including producers of only urolithin-A (UM-A), producers of urolithin-A, isourolithin-A, and urolithin-B (UM-B), and non-producers (UM-0)). In addition, the microbial metabolites (phenolic-derived postbiotics) such as equol, urolithins, valerolactones, enterolactone, and enterodiol, and 8-prenylnaringenin, among others, can exert differential health effects. The knowledge is updated and position is taken here on i) the two-way interaction between GM and polyphenols, ii) the evidence between phenolic-derived postbiotics and health, iii) the role of metabotypes as biomarkers of GM and the clustering of individuals depending on their metabotypes (metabotyping) to explain polyphenols' effects, and iv) the gut microbial metabolism of catecholamines to illustrate the intersection between personalized nutrition and precision medicine.A. Cortés-Martín, Dr.

show abstract

“…One of the important triggers of childhood obesity is the antibiotic use, which increases the adipogenesis and alters the microbiota composition (Li, Wang, et al, 2017). O-desmethylangolensin (ODMA) non-producer phenotype (individuals that are not capable of metabolizing the soy isoflavone daidzein to ODMA) was associated with obesity in peri-and post-menopausal women (Miller et al, 2017).…”

Section: Resultsmentioning

confidence: 99%

Gut Microbiota and Body Weight – A Review

Duca

Rusu

Chira

et al. 2018

Psihol. teme (Online)

View full text Add to dashboard Cite

La relación entre la microbioma intestinal y la resistencia a la insulina tiene un impacto clínico importante dado que la gente afectada por disbiosis tiene predisposiciones para desarrollar la obesidad, la diabetes mellitus tipo 2, la enfermedad de hígado graso no alcohólico, cánceres, enfermedades cardiovasculares, neurodegenerativas y psiquiátricas. La disbiosis puede convertirse en una inflamación crónica, obesidad o síndrome metabólico. Hemos hecho una revisión sistemática de los estudios dedicados al papel de la microbioma intestinal para el aumento de peso y la obesidad. Una búsqueda sistemática de datos recientes publicados en las bases de datos electrónicas se ha llevado a cabo usando la frase “gut microbiome and body weight and obesity”. Se ha excluido a los estudios que no contenían informaciones sobre la influencia de los cambios de la microbioma intestinal en la obesidad. La dieta occidental, uso de los antibióticos en la niñez, peso excesivo antes del embarazo, parto por cesárea y deficiencia de testosterona provocan la alteración de la microbioma y por consiguiente la apariencia de la obesidad. El predominio de firmicutes y géneros anaeróbicos, cambios en el microbioma y populación intestinal viral están implícitos en la etiología de la obesidad. Prebióticos, polifenoles, diferentes hierbas, medicamentos (antidiabéticos, calcio), ejercicio físico, consumo de fibras y cirugía bariátrica son las opciones terapéuticas más importantes. Tratamientos dietéticos personalizados, agentes antivirales y manipulación de la microbioma representarían nuevas metas en el tratamiento de la obesidad. Cada cambio en la composición cuantitativa o cualitativa de la microbioma influye en los componentes del síndrome metabólico, así que todas las estrategias para el tratamiento o prevención de la obesidad en niños o adultos deberían tener microbioma como su meta.

show abstract

Being overweight or obese is associated with harboring a gut microbial community not capable of metabolizing the soy isoflavone daidzein to O- desmethylangolensin in peri- and post-menopausal women

Cited by 38 publications

References 42 publications

The Human Metabolism of Nuts Proanthocyanidins does not Reveal Urinary Metabolites Consistent with Distinctive Gut Microbiota Metabotypes

The Human Metabolism of Nuts Proanthocyanidins does not Reveal Urinary Metabolites Consistent with Distinctive Gut Microbiota Metabotypes

Where to Look into the Puzzle of Polyphenols and Health? The Postbiotics and Gut Microbiota Associated with Human Metabotypes

Gut Microbiota and Body Weight – A Review

Contact Info

Product

Resources

About